Literature DB >> 23064662

Bone disease in pediatric chronic kidney disease.

Katherine Wesseling-Perry1.   

Abstract

Children with long-standing chronic kidney disease (CKD) display clinical symptoms of bone disease, including bony deformities and fractures, which contribute to long-standing disability. Abnormalities in skeletal mineralization occur in a substantial proportion of this population and may contribute to chronic morbidity. Underscoring the potential contribution of parameters other than bone turnover to bone disease in CKD, a new definition for renal osteodystrophy (ROD), emphasizing the assessment of three key histologic descriptors, i.e., bone turnover (T), mineralization (M), and volume (V) (TMV), has been recommended in the assessment of all patients with CKD. Although bone biopsy is the only available method for assessing all three recommended areas of bone histology, this invasive procedure is not routinely used in any clinical setting; thus, a true understanding of the prevalence of abnormal turnover, defective mineralization, and altered bone volume throughout the course of CKD is limited. Recent data, however, have shed light on the progression of renal ROD throughout the course of CKD, including its early stages, as well as on the alterations in cell biology that accompany ROD.

Entities:  

Mesh:

Year:  2012        PMID: 23064662      PMCID: PMC3594120          DOI: 10.1007/s00467-012-2324-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  59 in total

1.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

2.  Early skeletal and biochemical alterations in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Chi-Hong Tseng; Robert Elashoff; Joshua J Zaritsky; Ora Yadin; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 8.237

3.  Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.

Authors:  M C Monier-Faugere; Z Geng; H Mawad; R M Friedler; P Gao; T L Cantor; H H Malluche
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

4.  A novel mechanism for skeletal resistance in uremia.

Authors:  E Slatopolsky; J Finch; P Clay; D Martin; G Sicard; G Singer; P Gao; T Cantor; A Dusso
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

5.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Authors:  Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

6.  Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization.

Authors:  Liesbet Lieben; Ritsuko Masuyama; Sophie Torrekens; Riet Van Looveren; Jan Schrooten; Pieter Baatsen; Marie-Hélène Lafage-Proust; Tom Dresselaers; Jian Q Feng; Lynda F Bonewald; Mark B Meyer; J Wesley Pike; Roger Bouillon; Geert Carmeliet
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

7.  Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.

Authors:  Emilio Gonzalez-Parra; Maria Luisa Gonzalez-Casaus; Antonio Galán; Alberto Martinez-Calero; Victor Navas; Mariano Rodriguez; Alberto Ortiz
Journal:  Nephrol Dial Transplant       Date:  2011-03-24       Impact factor: 5.992

8.  Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.

Authors:  Ekaterini Siomou; Anna Challa; Nikoleta Printza; Vasileios Giapros; Fotini Petropoulou; Andromachi Mitsioni; Fotios Papachristou; Constantinos J Stefanidis
Journal:  Pediatr Nephrol       Date:  2011-04-09       Impact factor: 3.714

9.  Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.

Authors:  Yumie Rhee; Nicoletta Bivi; Emily Farrow; Virginia Lezcano; Lilian I Plotkin; Kenneth E White; Teresita Bellido
Journal:  Bone       Date:  2011-06-25       Impact factor: 4.398

10.  Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice.

Authors:  Neil Charles Wallace Mackenzie; Dongxing Zhu; Elspeth M Milne; Rob van 't Hof; Aline Martin; Leigh Darryl Quarles; Darryl Leigh Quarles; José Luis Millán; Colin Farquharson; Vicky Elisabeth MacRae
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  11 in total

1.  Renal formulas pretreated with medications alters the nutrient profile.

Authors:  Jacob M Taylor; Leah Oladitan; Susan Carlson; Jill M Hamilton-Reeves
Journal:  Pediatr Nephrol       Date:  2015-05-01       Impact factor: 3.714

2.  Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Authors:  Rukshana Shroff; Mandy Wan; Evi V Nagler; Sevcan Bakkaloglu; Mario Cozzolino; Justine Bacchetta; Alberto Edefonti; Constantinos J Stefanidis; Johan Vande Walle; Gema Ariceta; Günter Klaus; Dieter Haffner; Claus Peter Schmitt
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

3.  Pediatric CKD-MBD: existing and emerging treatment approaches.

Authors:  Rose M Ayoob; John D Mahan
Journal:  Pediatr Nephrol       Date:  2022-01-17       Impact factor: 3.651

Review 4.  Causes, mechanisms and management of paediatric osteoporosis.

Authors:  Outi Mäkitie
Journal:  Nat Rev Rheumatol       Date:  2013-04-16       Impact factor: 20.543

Review 5.  Interventions for metabolic bone disease in children with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-11-12

6.  Chronic kidney disease in children.

Authors:  Francesca Becherucci; Rosa Maria Roperto; Marco Materassi; Paola Romagnani
Journal:  Clin Kidney J       Date:  2016-06-05

Review 7.  Acute Kidney Injury and Pediatric Bone Health.

Authors:  Anisha Hegde; Michelle R Denburg; Dorey A Glenn
Journal:  Front Pediatr       Date:  2021-02-09       Impact factor: 3.418

8.  Correction of lower limb deformities in children with renal osteodystrophy by guided growth technique.

Authors:  C Gigante; A Borgo; M Corradin
Journal:  J Child Orthop       Date:  2017       Impact factor: 1.548

Review 9.  The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce.

Authors:  Louise McAlister; Pearl Pugh; Laurence Greenbaum; Dieter Haffner; Lesley Rees; Caroline Anderson; An Desloovere; Christina Nelms; Michiel Oosterveld; Fabio Paglialonga; Nonnie Polderman; Leila Qizalbash; José Renken-Terhaerdt; Jetta Tuokkola; Bradley Warady; Johan Vande Walle; Vanessa Shaw; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2019-10-30       Impact factor: 3.714

Review 10.  Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.

Authors:  Radomir Reszke; Katarzyna Kiliś-Pstrusińska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.